Search results
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
GuruFocus.com via Yahoo Finance· 13 hours agoThe company, a prominent biopharmaceutical entity focused on innovative therapies for eye diseases,...
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst - Glaukos...
Benzinga· 6 days agoThursday, Glaukos Corporation GKOS reported a first-quarter adjusted EPS loss of $(0.70), up from...
Q1 2024 Halozyme Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 27 minutes agoWe're also pleased to report two pipeline advancements. Firstly, our Agennix initiated registrational studies of efgartigimod subcutaneous with Enhanze for a new indication thyroid ...
Is Wegovy or Ozempic Better for Weight Loss?
MediaFeed via AOL· 5 days agoJacob Wackerhausen/Istockphoto The most common side effects of Ozempic include: Pancreatitis (inflammation of the pancreas) Diabetic retinopathy...
Looking for something to do in Bartlesville? We've got you covered
Examiner Enterprise via Yahoo News· 2 hours agoTriad Eye Clinic holds eye screenings for seniors 55+ at Elder Care. Testing and information provided by a licensed optometrist for glaucoma, cataracts, diabetic eye
5 health behaviors that can make you blind
Rolling Out· 19 hours agoMost of us are aware that certain diseases or injuries can lead to vision loss but not realize that everyday behaviors can also harm our sight.
Want to show teachers appreciation? A top Florida school gives them more freedom
WJHL· 2 days agoWaning job satisfaction over the last two decades has accompanied a decline in teachers’ sense of...
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 2 days agodropped nearly 30% in premarket trading Monday after the company said its experimental...
HanAll Biopharma initiates Phase III DED treatment trial
Clinical Trials Arena via Yahoo Finance· 2 days agoHanAll Biopharma has commenced the Phase III VELOS-4 trial for tanfanercept, a new topical...
EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint
Market Watch· 2 days agoEyePoint Pharmaceuticals said that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.
